CSL (CSLLY) NonCurrent Deferred Liabilities : $1,547 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CSL NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CSL's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $1,547 Mil.

CSL NonCurrent Deferred Liabilities Historical Data

The historical data trend for CSL's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL NonCurrent Deferred Liabilities Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

168.70

352.00

459.40

670.10

1,464.00

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															669.10	670.10	1,266.10	1,464.00	1,547.00

CSL NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of CSL's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.